Upadacitinib for stubborn eyelid dermatitis
Treatments studied
Part of Eyes & vision, Skin clinical trials.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have had eyelid dermatitis (a red, itchy rash on the eyelids) for at least 2 months.
- You have tried at least one prescription cream (such as a steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) that did not clear the rash.
- You are willing to stop using any other topical medication on your eyelids for one week before starting the study drug.
- You do not have a history of allergic reaction to upadacitinib, heart disease, stroke, or active infections like tuberculosis, hepatitis B, or hepatitis C.
- If you are a woman who could become pregnant, you agree to use effective birth control during treatment and for 4 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This trial tests whether upadacitinib, a drug that calms the immune system, can help people with autoimmune liver disease and severe itching from atopic dermatitis (eczema). It aims to reduce itching and improve liver health.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
This trial tests a pill called upadacitinib to see if it can reduce painful mouth sores and scalp hair loss caused by lichen planus. It may help people who have not gotten better with topical steroid creams.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
Hear when a new Eyelid Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.